Treating depressed children with antidepressants: more harm than benefit?

Area of Science:

• Child and Adolescent Psychiatry
• Pediatric Psychology
• Clinical Psychology

Background:

• The U.S. Food and Drug Administration (FDA) convened hearings in February 2004 regarding antidepressant safety in pediatric populations.
• Significant controversy emerged, leading to black box warnings highlighting increased suicidal behavior risk in children and young adults (up to age 25).

Purpose of the Study:

• To summarize antidepressant efficacy and safety data for children and adolescents.
• To provide psychologists with information to educate parents about the science of these treatments.
• To address parental questions regarding pediatric antidepressant use.

Main Methods:

• Review of scientific literature and data on antidepressant efficacy and safety in pediatric populations.
• Information synthesized from the American Psychological Association (APA) Report of the Working Group on Psychoactive Medications for Children and Adolescents.
• Content structured around common parental inquiries about antidepressant treatment.

Main Results:

• The article synthesizes current evidence on the effectiveness of antidepressants in treating childhood mental health disorders.
• Safety data, including risks and benefits, is critically evaluated in the context of pediatric use.
• The review addresses the complexities of psychopharmacological interventions for young patients.

Conclusions:

• Psychologists can play a crucial role in informing parents about the evidence base for antidepressant use in children.
• Understanding the efficacy and safety profile is essential for shared decision-making in pediatric mental health treatment.
• This review aims to demystify antidepressant treatment for young patients and their families.